‘Temple Is Not Made For India’: Deepinder Goyal Defends Pricing Of ₹85,000, Claims Device Is Made For Global Markets
New Delhi: Deepinder Goyal, Founder and CEO of Temple and founder of Zomato, has defended his new Temple device amid criticism over its pricing and technology claims, clarifying that it is designed as a fitness and artificial intelligence (AI) device and is not intended to diagnose or prevent diseases. Hello everyone. Happy Diwali! Thank you for your criticism, your support and your time over the…
New Delhi: Temple's CEO Deepinder Goyal has responded to criticism over the device's pricing and technological claims, asserting that it is designed for the global market and not intended for disease diagnosis. He emphasizes that Temple is a fitness and AI device, with no medical claims, and that it does not replace the need for medical consultations.
Goyal clarifies that users can wait for further research and reviews before deciding to purchase the device. He explains that the company priced the product based on its perceived value and that 1% of the devices sold are expected to be in India. Goyal also addresses the device's main features, stating that Brain Flow is not the main focus and that Entropy is the company's primary focus.
He mentions that Roomdeaf AI is an expansion of the device's capabilities and the company's broader vision for Temple.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
